Skip to content
Open access · CC-BY via OpenAlex

Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment

Ellen Quarles, Nathan Basisty, Ying Ann Chiao, Gennifer E. Merrihew, Haiwei Gu, Mariya T. Sweetwyne, Jeanne Fredrickson, Ngoc‐Han Nguyen, Maria V. Razumova, Kristina B. Kooiker, Farid Moussavi‐Harami, Michael Regnier, Christopher L. Quarles, Michael J. MacCoss, Peter S. Rabinovitch

Aging Cell · 2019 · ▲ 102 citations

Abstract

Even in healthy aging, cardiac morbidity and mortality increase with age in both mice and humans. These effects include a decline in diastolic function, left ventricular hypertrophy, metabolic substrate shifts, and alterations in the cardiac proteome. Previous work from our laboratory indicated that short-term (10-week) treatment with mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), an mTORC1 inhibitor, improved measures of these age-related changes. In this report, we demonstrate that the rapamycin-dependent improvement of diastolic function is highly persistent, while decreases in both cardiac hypertrophy and passive stiffness are substantially persistent 8 weeks after cessation of an 8-week treatment of rapamycin in both male and female 22- to 24-month-old C57BL/6NIA mice. The proteomic and metabolomic abundance changes that occur after 8 weeks of rapamycin treatment have varying persistence after 8 further weeks without the drug. However, rapamycin did lead to a persistent increase in abundance of electron transport chain (ETC) complex components, most of which belonged to Complex I. Although ETC protein abundance and Complex I activity were each differentially affected in males and females, the ratio of Complex I activity to Complex I protein abundance was equally and persistently reduced after rapamycin treatment in both sexes. Thus, rapamycin treatment in the aged mice persistently improved diastolic function and myocardial stiffness, persistently altered the cardiac proteome in the absence of persistent metabolic changes, and led to persistent alterations in mitochondrial respiratory chain activity. These observations suggest that an optimal translational regimen for rapamycin therapy that promotes enhancement of healthspan(definition) may involve intermittent short-term treatments.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1111/acel.13086
Canonical
link ↗
Fetched
2026-06-13 MST

Cite this

APA
Quarles, E., Basisty, N., Chiao, Y.A., Merrihew, G.E., Gu, H., Sweetwyne, M.T., Fredrickson, J., Nguyen, N., Razumova, M.V., Kooiker, K.B., Moussavi‐Harami, F., Regnier, M., Quarles, C.L., MacCoss, M.J., &amp; Rabinovitch, P.S. (2019). Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13086
Vancouver
Quarles E, Basisty N, Chiao YA, Merrihew GE, Gu H, Sweetwyne MT, et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell. 2019. doi:10.1111/acel.13086.
BibTeX
@article{ellen2019Rapamy, title = {Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment}, author = {Ellen Quarles and Nathan Basisty and Ying Ann Chiao and Gennifer E. Merrihew and Haiwei Gu and Mariya T. Sweetwyne and Jeanne Fredrickson and Ngoc‐Han Nguyen and Maria V. Razumova and Kristina B. Kooiker and Farid Moussavi‐Harami and Michael Regnier and Christopher L. Quarles and Michael J. MacCoss and Peter S. Rabinovitch}, journal = {Aging Cell}, year = {2019}, doi = {10.1111/acel.13086}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.